OnlyOI

OnlyOI is a clinical-stage biotechnology company focused on developing breakthrough treatments for rare bone diseases, particularly Osteogenesis Imperfecta (OI). The company's lead program, OI-001, is a humanized monoclonal antibody that inhibits sclerostin to promote bone formation and increase bone mineral density. OnlyOI is committed to improving the quality of life for patients with brittle bone disease by providing effective therapeutic options where few currently exist. Headquartered in Shanghai, the company is supported by leading venture capital firms and is actively advancing its pipeline through clinical trials in China and potentially global markets. By targeting the underlying biological mechanisms of bone fragility, OnlyOI aims to become a leader in the metabolic bone disease space.